-
2024-517147-31-00
9
2025-05-23
Tumours, Gynecological
-
2024-515395-12-00
4
2025-05-22
Adults with ADHD and moderate to severe depression
-
2024-513959-33-00
4
2025-05-13
Asthma
-
2024-516605-23-00
5
2025-05-12
relapsed/refractory nodal T cell lymphoma with T follicular helper (TF
-
2023-510155-37-00
5
2025-05-08
Hypomethylating agent (HMA) naive myelodysplastic syndromes
Myelodyspl
-
2024-511435-10-00
1
2025-04-30
Hepatocellular Carcinoma
-
2024-516009-22-00
5
2025-04-30
myelodysplastic neoplasms/syndromes (MDS)
-
2023-507878-41-00
4
2025-04-25
Acute myeloid leukemia
-
2024-512679-11-00
5
2025-04-25
unborn baby with developmental disorder of the left side of the heart
-
2024-516367-80-00
4
2025-04-24
resectable and borderline resectable stage IIIA/B NSCLC
-
2024-516173-76-01
5
2025-04-22
HER2-positive or HER2-low (incl. ultra-low) early breast cancer
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2024-511495-32-00
5
2025-04-16
Chronic Phase Chronic Myeloid Leukemia
-
2024-512876-37-00
5
2025-04-11
Peripheral Arterial Disease (PAD)
-
2023-504180-16-00
5
2025-04-07
Advanced Breast Cancer
-
2023-508076-11-00
5
2025-04-01
Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2022-500747-21-00
4
2025-02-27
Geographic Atrophy
-
2023-510292-65-00
5
2025-02-25
chronic graft-versus-host disease
-
2023-509632-26-00
9
2025-02-11
Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
-
2023-509806-31-00
4
2025-02-11
Non-Small Cell Lung Cancer
-
2024-511037-35-00
4
2025-01-31
Cyclosporine A is a well known medication and is used to prevent rejec
-
2023-505320-54-00
4
2025-01-30
Multiple System Atrophy
-
2023-510322-32-00
5
2025-01-27
patients with incurable, metastatic/recurrent head and neck squamous c